What FDA PDUFA VII Performance Goals and Procedures 2023-2027 requires
The FDA PDUFA VII requires prescription drug manufacturers to meet specific performance goals and procedures for the review of new drug applications, as outlined in Section 735(1) of the Federal Food, Drug, and Cosmetic Act.
Pillar: Pharmaceuticals & Life Sciences · Authority: U.S. Food and Drug Administration · Version: 1.0.1 · Last updated:
Primary source: https://www.fda.gov/industry/prescription-drug-user-fee-amendments/pdufa-vii-fiscal-years-2023-2027
SHA-256 integrity: 80f0571eef38edadec51c5c629b46c7f3cf6a0776bc098765acf13cdc5d7bfc3
Primary Citations — 6 traced to source
- Federal Food, Drug, and Cosmetic Act, Section 735(1)
- PDUFA VII Performance Goals and Procedures 2023-2027, Goal 1: Review Timelines
+ 4 more citations (full bibliography, deterministic workflow, actionable schema and crosswalks) included in the vault unlock — $0.01 via Skyfire / L402 / Direct Base USDC.
Access
- Discovery (free): /api/v1/nodes/fda-pdufa-vii-goals-letter-2022.json — 6-field metadata
- Vault (full node): /api/v1/vault/nodes/fda-pdufa-vii-goals-letter-2022.json — full 13-key payload, $0.01 USDC (L402/Skyfire/Direct Base)
- Canonical URL: https://bidda.com/intelligence/fda-pdufa-vii-goals-letter-2022
- Back to registry: Browse all 10,085 compliance nodes